Increased production and secretion of HGF α‐chain and an antagonistic HGF fragment in a human breast cancer progression model

作者: Theodore G. Wright , Vinay K. Singh , John J. Li , Jonathan H. Foley , Fred Miller

DOI: 10.1002/IJC.24364

关键词:

摘要: Invasive human breast carcinomas frequently coexpress increased hepatocyte growth factor (HGF) and its receptor Met, suggesting that establishment of an autocrine HGF loop is important in malignant disease. This study examines the expression patterns Met activation during tumorigenesis metastasis using a MCF10A-based model Ha-Ras-induced cancer progression. Deregulation cadherin-based cell-cell adhesions, decreased cytokeratins 8/18 activity matrix metalloproteinases such as MMP-2 occurs premalignant (metastatic) cell lines compared to parental nonmalignant line. Compared benign parent line, exhibit secretion full length α-chain elevated tyrosine phosphorylation complete medium. Interestingly, cells also secrete ∼55 kDa fragment. Epitope mapping fragment supports presence N-terminal domain with truncation C-terminal domain. The shows mobility SDS-PAGE faster than α-chain, but slightly slower NK4, previously established antagonist HGF. separated binds animmobilized Met-IgG fusion protein, inhibits both HGF/Met-IgG binding HGF-induced Met-tyrosine phosphorylation. These results are first demonstration antagonistic secreted carcinoma progression, which may have negative regulatory effect on signaling epithelial cells. © 2009 UICC

参考文章(52)
Nobuaki Funata, Hiroko Iwanari, Kiyoshi Sekiguchi, Takeshi Tominaga, Masakazu Toi, Tadaaki Taniguchi, Michio Asano, Takayuki Ueno, Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clinical Cancer Research. ,vol. 4, pp. 659- 664 ,(1998)
S R Wolman, L Tait, G H Heppner, P J Dawson, F R Miller, MCF10AT: a model for the evolution of cancer from proliferative breast disease. American Journal of Pathology. ,vol. 148, pp. 313- 319 ,(1996)
N.A. Lokker, M.R. Mark, E.A. Luis, G.L. Bennett, K.A. Robbins, J.B. Baker, P.J. Godowski, Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. The EMBO Journal. ,vol. 11, pp. 2503- 2510 ,(1992) , 10.1002/J.1460-2075.1992.TB05315.X
Benjamin E. Turk, Lisa L. Huang, Elizabeth T. Piro, Lewis C. Cantley, Determination of protease cleavage site motifs using mixture-based oriented peptide libraries Nature Biotechnology. ,vol. 19, pp. 661- 667 ,(2001) , 10.1038/90273
A B Tuck, A Boag, B E Elliott, E E Sterns, M Park, Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. American Journal of Pathology. ,vol. 148, pp. 225- 232 ,(1996)
N.A. Lokker, P.J. Godowski, Generation and characterization of a competitive antagonist of human hepatocyte growth factor, HGF/NK1. Journal of Biological Chemistry. ,vol. 268, pp. 17145- 17150 ,(1993) , 10.1016/S0021-9258(19)85314-0
Anne Vincent-Salomon, Jean Paul Thiery, Host microenvironment in breast cancer development: Epithelial–mesenchymal transition in breast cancer development Breast Cancer Research. ,vol. 5, pp. 101- 106 ,(2003) , 10.1186/BCR578
Bruce E Elliott, Wesley L Hung, Alexander H Boag, Alan B Tuck, The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Canadian Journal of Physiology and Pharmacology. ,vol. 80, pp. 91- 102 ,(2002) , 10.1139/Y02-010
Ming-Sound Tsao, Ye Yang, Alexander Marcus, Ni Liu, Lunjun Mou, Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non–small-cell lung cancer Human Pathology. ,vol. 32, pp. 57- 65 ,(2001) , 10.1053/HUPA.2001.21133
Luigi Naldini, Elisa Vigna, Alberto Bardelli, Antonia Follenzi, Francesco Galimi, Paolo M. Comoglio, Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. Journal of Biological Chemistry. ,vol. 270, pp. 603- 611 ,(1995) , 10.1074/JBC.270.2.603